Influenza treatment options remain limited, and a persistent challenge in clinical care is that most existing antivirals must be administered within the first one to two days of infection to be effective. By the time most patients seek medical attention, that window has already closed. A new study from Penn State researchers, published in the journal Respiratory Research, identifies a protein called GM-CSF as a potential influenza treatment that could work even after the infection is already established, offering a significantly broader therapeutic window than currently available options.
What GM-CSF Is and How It Relates to Influenza Treatment
GM-CSF is a cytokine, a type of signaling molecule that alerts other cells to the presence of infection or tissue damage. While influenza and other viruses all trigger cytokine responses, influenza is particularly associated with a surge in a cytokine called type II interferon, which drives high levels of lung inflammation and is believed to be a key reason why influenza can be more severe than other respiratory viruses such as rhinovirus or respiratory syncytial virus.
Previous research had suggested that mice born with naturally elevated levels of GM-CSF were protected from influenza, but those studies did not address whether introducing GM-CSF after infection was already underway could produce the same protective effect. That distinction is clinically critical for any viable influenza treatment approach, since patients do not arrive for care before symptoms begin.
How the Influenza Treatment Study Was Conducted
To model a real world influenza treatment scenario, the Penn State team used mice engineered with a special gene that allows them to produce GM-CSF in their lungs when given the antibiotic doxycycline. Crucially, the researchers waited three days after infecting the mice with influenza before administering doxycycline and triggering GM-CSF production. This delay was intentional, designed to replicate the typical pattern of human illness in which patients do not seek care on the first day of symptoms.
At 13 days after infection, 90 percent of the mice that had received GM-CSF were still alive, compared to 50 percent of those that had not. The GM-CSF treated mice also showed better overall lung function throughout the study period.
Why GM-CSF Suppresses Lung Inflammation During Influenza
One of the most counterintuitive findings in the study was that GM-CSF, a cytokine generally associated with promoting inflammation, actually suppressed the inflammatory response during influenza infection. Using RNA sequencing to analyze macrophage gene activity in the lungs, the researchers found that GM-CSF knocked down the response to type II interferon, the cytokine responsible for the most severe lung inflammation seen in influenza patients.
Lead researcher E. Scott Halstead, assistant professor of pediatrics at Penn State College of Medicine, noted that the mechanism behind this suppression is not yet fully understood and will be the subject of future investigations. What is clear from the data is that GM-CSF reduced the inflammatory cascade that makes influenza dangerous, even when administered several days after the onset of infection.
The Path Toward Clinical Trials for This Influenza Treatment
The broader therapeutic window offered by GM-CSF is one of its most significant advantages over existing influenza treatments. Antivirals like Tamiflu are largely ineffective once the first day or two of infection has passed. GM-CSF, based on the mouse data, continues to provide benefit several days into the illness, which aligns far more closely with how patients actually present in clinical settings.
Halstead reported that he is working with the FDA to obtain approval to begin a clinical trial testing GM-CSF as an influenza treatment in people with viral pneumonia. If the benefit seen in mice translates to humans, this approach could represent a meaningful addition to the influenza treatment landscape for patients who are no longer candidates for standard antiviral therapy.
To read more about infectious disease research, visit the FOMAT blog. FOMAT conducts infectious disease clinical trials at sites across the United States. To learn more about active studies, visit FOMAT’s patient studies page.
For the full source, see the original article at Penn State News.